Who makes HF treatment according to Swedish guidelines?

HF treatment according to Swedish guidelines is developed by AstraZeneca.

What development phase is HF treatment according to Swedish guidelines in?

HF treatment according to Swedish guidelines is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

HF treatment according to Swedish guidelines

AstraZeneca · FDA-approved active Small molecule Quality 0/100

AstraZeneca's HF treatment, aligned with Swedish guidelines, holds a significant market position as a marketed drug. The key composition patent, expiring in 2028, provides a strong competitive advantage by protecting the drug's unique formulation. The primary risk lies in potential competition post-patent expiry, which could erode market share and revenue.

At a glance

Generic name	HF treatment according to Swedish guidelines
Sponsor	AstraZeneca
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HF treatment according to Swedish guidelines CI brief — competitive landscape report
HF treatment according to Swedish guidelines updates RSS · CI watch RSS
AstraZeneca portfolio CI